Patents Examined by Leslie A. Royds Draper
  • Diazepane derivatives and uses thereof
    Patent number: 10308653
    Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: June 4, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Dennis Buckley
  • Boron-containing small molecules as antiprotozoal agents
    Patent number: 10301329
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 28, 2019
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Daitao Chen, Matthew Orr, Jessica Sligar, Robert Jacobs, Jacob J. Plattner
  • Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
    Patent number: 10300031
    Abstract: The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: May 28, 2019
    Assignee: Trinity Laboratories Inc.
    Inventor: Chandra Ulagaraj Singh
  • Therapeutic compounds and methods
    Patent number: 10272055
    Abstract: Biguanide compounds and salts thereof are disclosed. Also disclosed are pharmaceutical compositions and therapeutic methods for treating certain diseases including cancer such as breast cancer.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: April 30, 2019
    Assignees: Regents of the University of Minnesota, The Regents of the University of California
    Inventors: David A. Potter, Zhijun Guo, Elizabeth Amin, Gunda Georg, Tom Poulos, Irina Sevrioukova
  • Method of increasing intratumoral pHe and reducing acid-mediated invasion
    Patent number: 10258607
    Abstract: A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO3, 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), cholamine chloride, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). The method can further include the step of pretreating with one or more chemotherapeutic agents.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 16, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Robert J. Gillies, David L. Morse, Ariosto Siqueira Silva, Arig A. Ibrahim Hashim, Robert A. Gatenby, Gary Martinez
  • Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
    Patent number: 10258600
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 16, 2019
    Assignees: Trustees of Boston University, Boston Medical Center, Northeastern University
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Organic compounds
    Patent number: 10245260
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: April 2, 2019
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
    Patent number: 10231933
    Abstract: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: March 19, 2019
    Assignee: CRYXA LLC
    Inventors: F. Joseph Daugherty, John R. Palmer, Michael S. Tempesta
  • Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
    Patent number: 10226429
    Abstract: An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: March 12, 2019
    Assignee: CRYXA LLC
    Inventors: F. Joseph Daugherty, John R. Palmer, Jr., Michael S. Tempesta
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 10214528
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 26, 2019
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Compositions and methods for inhibiting the growth of neisseria gonorrhoeae
    Patent number: 10201526
    Abstract: Compositions and methods for preventing and treating Neisseria gonorrhoeae infection with AR-12 alone or in combination with antibiotics are provided.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 12, 2019
    Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation Foundation
    Inventors: Jennifer Edwards, Alexander Zukiwski
  • Methods and compounds for increasing red blood cell survival
    Patent number: 10165772
    Abstract: Methods and compositions for increasing red blood cell survival and/or inhibiting hemolysis using indole-comprising compounds are described. Such methods and compositions may be useful for blood and blood product storage and preservation applications.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: January 1, 2019
    Inventor: Édouard Kouassi
  • Deoxynojirimycin derivatives and methods of their using
    Patent number: 10144727
    Abstract: The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: December 4, 2018
    Assignee: Emergent Virology LLC
    Inventors: Urban Ramstedt, Raju Penmasta, Hitesh Batra, Tam Nguyen
  • Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
    Patent number: 10137127
    Abstract: A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 27, 2018
    Assignee: Loxo Oncology, Inc.
    Inventors: Mark Reynolds, Steven A. Smith
  • Tablet formulation for CGRP active compounds
    Patent number: 10117836
    Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 6, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • 4-hydroxybutyric acid analogs
    Patent number: 10040748
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: August 7, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Adam J. Morgan
  • Compositions for preventing and/or treating lysosomal storage disorders
    Patent number: 10035766
    Abstract: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: July 31, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Inhibitors of metallo-?-lactamase-enzymes
    Patent number: 10016383
    Abstract: The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of one or more ?-lactam antibiotics and one or more compounds of Formula I: (I) for treatment of a metallo-B-lactamase-expressing bacterial infection or a disease, disorder or condition arising from a metallo-B-lactamase-expressing bacterial infection.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: July 10, 2018
    Assignee: McMaster University
    Inventors: Gerry Wright, Wenliang Wang, Andrew King
  • 4-benzylsulfonyl-2-butenenitrile
    Patent number: 9987246
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 5, 2018
    Assignee: Olatec Therapeutics LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, Scott A. Goodrich
  • Sulfonamide compounds for inhibition of metastatic tumor growth
    Patent number: 9962398
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 8, 2018
    Assignee: Welichem Biotech Inc.
    Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta